Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews


Print Page Follow BioNews on Twitter BioNews RSS feed

Like the Progress Educational Trust on Facebook



The Fertility Show





Stem cell transplants hold hope for treating blindness

31 January 2012

By Rosemary Paxman

Appeared in BioNews 642

A clinical trial testing the safety of using human embryonic stem cell (hESC) in the treatment of progressive eye conditions has been carried out by researchers in the USA.

The phase I/II trial looked at the safety of transplanting hESCs into two people with different types of eye disease: one person with Stargardt's macular dystrophy and one person with dry age-related macular degeneration (AMD). The researchers found no signs of rejection or abnormal cell growth indicating that hESCs may one day be safely used for therapeutic use in humans.

Researchers at Advanced Cell Technology, a biotech company which develops stem cell-based technologies, along with the Jules Stein Eye Institute at the University of California, Los Angeles, cultivated the hESCs using mouse skin cells into cell types found inside the eye. The cells were then purified and subsequently injected into specific locations within the eye.

'The cells seem to have transplanted into both patients without abnormal proliferation, tumour formation, graft rejection or any untoward pathological reactions or safety signals', the researchers said. However, they added that follow-up studies were needed to further establish the safety of the procedure. 

After the injections of stem cells, the patients also demonstrated a functional improvement in their vision. The patient with Stargardt's macular degeneration could previously only determine hand motions, but two weeks after the injections they could reportedly count fingers using their treated eye. The patient with AMD also reported an improvement in vision, although the researchers could not see that the cells had survived the procedure.

Professor Daniel Brison, co-director of the North West Embryonic Stem Cell Centre, Manchester, described the results as a 'very exciting moment for embryonic stem cell therapies'.

'Although the study is limited to safety considerations, very small in scope, and at a very early stage, this is nonetheless a ground breaking moment for embryonic stem cell therapies', he said.

Professor Chris Mason, chair of Regenerative Medicine Bioprocessing, University College London described the findings as 'only the start of gathering the necessary safety data before it is possible to test if the therapy will have an impact on patients' vision'.

'Overall the process of testing for safety and efficacy is likely to take a minimum of 5-10 years before the potential therapy could enter routine clinical practice', he said.

The study was published in the Lancet.

 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

17 June 2013 - by Rhys Baker 
A 'non-invasive' method for delivering gene therapy into the eye has been developed by US researchers... [Read More]
28 May 2012 - by Ana Pallesen 
Two patients with corneal blindness have become the first people in the UK to have stem cells transplanted into their eyes in order to restore their sight... [Read More]
12 March 2012 - by Dr Nadeem Shaikh 
A potential stem cell therapy for glaucoma – a degenerative eye condition that can lead to blindness – has yielded positive results in animal tests... [Read More]
13 February 2012 - by Rosemary Paxman 
Following a brutal acid attack, Katie Piper has undergone 109 operations to rebuild her face, however it is the 110th that could change her life. By using pioneering stem cell treatment, Katie hopes to restore the sight to her badly damaged left eye... [Read More]
13 February 2012 - by Maria Botcharova 
Three women have reported a significant improvement in sight following gene therapy in both their eyes. Initially, they received the therapy in just one eye, but this latest study demonstrates the treatment was also successful in the other... [Read More]

31 October 2011 - by Victoria Kay 
A British man has become the first person to receive an advanced gene therapy treatment in a bid to save his sight. Jonathan Wyatt, aged 63, is the first of 12 patients to have the experimental procedure to try and halt the progression of his genetic eye disorder, choroideraemia. While he still has some sight, if left untreated, he would eventually become blind... [Read More]
26 September 2011 - by Dr Rachael Panizzo 
UK scientists have been granted approval to begin the first clinical trial using embryonic stem cells (ES cells) in Europe, which they hope could lead to an effective treatment for a degenerative eye disease causing blindness... [Read More]
18 July 2011 - by Dr Sophie Pryor 
Doctors in the USA have begun treating patients in two clinical trials for degenerative eye diseases. The studies at the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA), will test whether specialised eye cells, which have been produced from human embryonic stem cells (hESCs), can be used to treat dry age-related macular degeneration (dry AMD) and Stargardt's macular dystrophy.... [Read More]
20 June 2011 - by Dr Rebecca Robey 
Two clinical trials to test whether embryonic stem cells can treat two incurable eye disorders have been launched in the USA. Twenty-four patients will be treated during the trials at the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA)... [Read More]
11 April 2011 - by Dr Rachael Panizzo 
Embryonic stem cells have been used to generate a basic retina, the part of the eye that detects light and is needed for vision. The retinal tissue could be used to treat some forms of blindness, such as retinitis pigmentosa and age-related macular degeneration, and to investigate and screen potential new drugs for a range of eye diseases.... [Read More]

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

 


 

- click here to enquire about using this story.

Printer Friendly Page

Published by the Progress Educational Trust
PET CONFERENCE
COMMERCIALISATION OF LIFE


Lord Robert Winston, Professor of Science and Society at Imperial College London and speaker at the Progress Educational Trust's conference 'The Commercialisation of Life', taking place in central London on Tuesday 2 December

London, 2 December
Click HERE for details

FREE EVENT
HOW SHOULD YOUR DNA BE USED IN THE 100,000 GENOMES PROJECT?


'Genetic Conditions: How Should Your DNA Be Used in the 100,000 Genomes Project?', a FREE public event being organised by the Progress Educational Trust in central London on the evening of Thursday 6 November 2014

London, 6 November
Click HERE for details

Good Fundraising Code

Advertise your products and services HERE - click for further details